OR WAIT 15 SECS
The new director general has stepped into the European generic and biosimilar medicines industries at a challenging time when the trade association is facing numerous priority issues on the European agenda.
Adrian van den Hoven has been appointed as the new director general of the European Generic Medicines Association (EGA). The new director general is warmly welcomed by EGA’s president, Gudbjorg Edda Eggertsdottir, who commented in a press statement that Adrian van den Hoven’s expertise and proven track record of high level advocacy with European Institutions, large portfolio industries and other European stakeholders, will firmly drive forward EGA’s assignments.
Adrian van den Hoven will be working with EGA members to strengthen the generic and biosimilar medicines industries in Europe and to increase access to high quality medicines for patients at reasonable costs for member state healthcare budgets.
Adrian van den Hoven obtained his doctorate in political science from the University of Nice, France in 2000. He was previously deputy-director general of BUSINESSEUROPE, where his responsibilities included trade negotiations, bilateral relations as well as industrial, energy, environmental, and research policy in the International Relations and Industry Departments. He also has experience as an international relations researcher and an adjunct professor in Italy, France, and Canada.